Revision 1

Store at -20C

#14752

Kv7.2 (D9L5S) Rabbit mAb

Cell Signaling TECHNOLOGY®

Orders: 877-616-CELL (2355)
orders@cellsignal.com

Support: 877-678-TECH (8324)

Web: info@cellsignal.com
cellsignal.com

3 Trask Lane | Danvers | Massachusetts | 01923 | USA

For Research Use Only. Not for Use in Diagnostic Procedures.

Applications:	Reactivity:	Sensitivity:	MW (kDa):	Source/Isotype:	UniProt ID:	Entrez-Gene Id:
W, IP	H M R	Endogenous	95	Rabbit IgG	#O43526	3785

Product Usage Information

Application	Dilution
Western Blotting	1:1000
Immunoprecipitation	1:50

Storage

Supplied in 10 mM sodium HEPES (pH 7.5), 150 mM NaCl, 100 µg/ml BSA, 50% glycerol and less than 0.02% sodium azide. Store at –20°C. Do not aliquot the antibody.

Specificity/Sensitivity

Kv7.2 (D9L5S) Rabbit mAb recognizes endogenous levels of total Kv7.2 protein. This antibody does not cross-react with Kv7.3 protein.

Source / Purification

Monoclonal antibody is produced by immunizing animals with a synthetic peptide corresponding to residues near the amino terminus of human Kv7.2 protein.

Background

The voltage gated potassium channel Kv7.2 (KCNQ2) associates with its family member Kv7.3 (KCNQ3) to form an M-channel that is involved in synaptic input response and sub-threshold excitability of neurons (1). This heteromeric channel generates the M-current, a slowly activating and deactivating potassium conductance that determines the neuronal excitability (2,3). Expression of these two M-channel proteins is mainly seen within the central nervous system, with both Kv7.2 and Kv7.3 expressed post-synaptically in the human cortex and hippocampus (4). The calcium-binding protein calmodulin binds two separate sites in Kv7.2 to influence exit of the channel protein from the endoplasmic reticulum and translocation to the plasma membrane (5). Mutations in the corresponding *KCNQ2* gene cause benign familial neonatal seizures-1 (BFNS1), an autosomal dominant form of epilepsy characterized by seizure clusters closely following birth (6,7).

Background References

1. Stewart, A.P. et al. (2012) *J Biol Chem* 287, 11870-7.
2. Wang, H.S. et al. (1998) *Science* 282, 1890-3.
3. Smith, J.S. et al. (2001) *J Neurosci* 21, 1096-103.
4. Cooper, E.C. et al. (2000) *Proc Natl Acad Sci U S A* 97, 4914-9.
5. Alaimo, A. et al. (2013) *J Cell Sci* 126, 244-53.
6. Miraglia del Giudice, E. et al. (2000) *Eur J Hum Genet* 8, 994-7.
7. Dedek, K. et al. (2001) *Proc Natl Acad Sci U S A* 98, 12272-7.

Species Reactivity

Species reactivity is determined by testing in at least one approved application (e.g., western blot).

Western Blot Buffer

IMPORTANT: For western blots, incubate membrane with diluted primary antibody in 5% w/v BSA, 1X TBS, 0.1% Tween® 20 at 4°C with gentle shaking, overnight.

Applications Key

W: Western Blotting **IP:** Immunoprecipitation

Cross-Reactivity Key

H: Human **M:** Mouse **R:** Rat

Trademarks and Patents

Limited Uses

Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products any trademarks, trade names, logos, patent or copyright notices or markings, (d) use the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.